Published finding — does the expert body still believe it?
Grade 3 or 4 treatment-related adverse events occur significantly more frequently with nivolumab plus ipilimumab (55.0%) than with nivolumab monotherapy (16.3%) or ipilimumab monotherapy (27.3%) in untreated metastatic melanoma patients.
TL;DR · AI-generated
Among previously untreated patients with metastatic melanoma, nivolumab alone or combined with ipilimumab resulted in significantly longer progression-free survival than ipILimumab alone, and in patients with PD-L1-negative tumors, the combination of PD-1 and CTLA-4 blockade was more effective than either agent alone.
Author-implied confidence
95%
Status
DRAFT
Your position — does this noeme still stand given current evidence?
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
1 event · 1 snapshot
posterior drift
98% → 98% (0pp · 1 point)
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
· openalex W2166662937 · s2 f1d33462
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.1063
Pembrolizumab is associated with lower rates of grade 3-5 treatment-related adverse events (10.1–13.3%) compared with ipilimumab (19.9%) in patients with advanced melanoma.
0.1496
In previously untreated patients with unresectable stage III/IV melanoma, nivolumab plus ipilimumab achieves a median progression-free survival of 11.5 months versus 2.9 months with ipilimumab alone (HR 0.42, P<0.001).
0.1503
In previously untreated metastatic melanoma patients with PD-L1-negative tumors, nivolumab plus ipilimumab produces longer progression-free survival (11.2 months) than nivolumab monotherapy (5.3 months).
0.1680
The CheckMate-067 trial's stated primary conclusion — Nivolumab + ipilimumab combination yields superior long-term survival in advanced melanoma vs. either monotherapy. — replicates in independent cohorts.
0.1866
In previously untreated metastatic melanoma patients with PD-L1-positive tumors, nivolumab monotherapy achieves equivalent median progression-free survival (14.0 months) to nivolumab plus ipilimumab combination therapy.
0.1901
Grade 3 or 4 adverse events, including pneumonia, occur at similar rates in durvalumab-treated (29.9%) and placebo-treated (26.1%) stage III NSCLC patients receiving consolidation therapy after chemoradiotherapy.